Key points are not available for this paper at this time.
Abstract Human Biomonitoring (HBM) refers to the analysis of xenobiotics or their metabolites in human biological matrices such as blood or urine. It therefore encompasses all exposure routes and reflects the actual individual exposure. In order to perform reliable and informative HBM-based exposure and risk assessments, several prerequisites must be fulfilled. In particular, if the relation between biomarker levels and safe exposure levels from occupational or epidemiological studies is unknown, the prior investigation of a substance’s toxicokinetics is essential for risk assessment. Human metabolism studies can be used to obtain toxicokinetic data and derive urinary excretion fractions (FUE), necessary for rugged pharmacokinetic models and useful in the derivation of health-based guidance values. This presentation will give a brief introduction to HBM, outline the effect of a substance’s toxicokinetics on biomarker and matrix selection for HBM, and explain the workflow of human metabolism studies.
Katharina E. Ebert (Sat,) studied this question.